Abiomed (FRA:AIO) Cash Flow from Financing : €-135 Mil (TTM As of Sep. 2022)

View and export this data going back to 1987. Start your Free Trial

What is Abiomed Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Sep. 2022, Abiomed paid €113 Mil more to buy back shares than it received from issuing new shares. It received €0 Mil from issuing more debt. It paid €0 Mil more to buy back preferred shares than it received from issuing preferred shares. It received €0 Mil from paying cash dividends to shareholders. It received €2 Mil on other financial activities. In all, Abiomed spent €111 Mil on financial activities for the three months ended in Sep. 2022.

Abiomed Cash Flow from Financing Historical Data

The historical data trend for Abiomed's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abiomed Cash Flow from Financing Chart

Abiomed Annual Data

Trend

Mar13

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Cash Flow from Financing

Get a 7-Day Free Trial

-7.41

-49.36

-106.53

-6.78

-2.00

Abiomed Quarterly Data
	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Cash Flow from Financing	Get a 7-Day Free Trial															5.68	-5.45	4.31	-22.64	-111.28

Abiomed Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Abiomed's Cash from Financing for the fiscal year that ended in Mar. 2022 is calculated as:

	Cash Flow from Financing		(A: Mar. 2022 )
=	Issuance of Stock	+	Repurchase of Stock	+	Net Issuance of Debt	+	Net Issuance of Preferred Stock	+	Cash Flow for Dividends	+	Other Financing
=	0	+	0	+	0	+	0	+	0	+	0
=	0

Abiomed's Cash from Financing for the quarter that ended in Sep. 2022 is:

	Cash Flow from Financing		(Q: Sep. 2022 )
=	Issuance of Stock	+	Repurchase of Stock	+	Net Issuance of Debt	+	Net Issuance of Preferred Stock	+	Cash Flow for Dividends	+	Other Financing
=	0	+	-113.227	+	0	+	0	+	0	+	1.943
=	-111

Cash Flow from Financing for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was €-135 Mil.

Abiomed (FRA:AIO) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Abiomed's issuance of stock for the three months ended in Sep. 2022 was €0 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Abiomed's repurchase of stock for the three months ended in Sep. 2022 was €-113 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Abiomed's net issuance of debt for the three months ended in Sep. 2022 was €0 Mil. Abiomed received €0 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Abiomed's net issuance of preferred for the three months ended in Sep. 2022 was €0 Mil. Abiomed paid €0 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Abiomed's cash flow for dividends for the three months ended in Sep. 2022 was €0 Mil. Abiomed received €0 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Abiomed's other financing for the three months ended in Sep. 2022 was €2 Mil. Abiomed received €2 Mil on other financial activities.

Abiomed Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Abiomed's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.

Abiomed (FRA:AIO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Abiomed Inc (FRA:AIO) » Definitions » Cash Flow from Financing

Comparable Companies

Traded in Other Exchanges

N/A

Address

22 Cherry Hill Drive, Danvers, MA, USA, 01923

Website

https://www.abiomed.com

Abiomed Inc provides temporary mechanical circulatory support devices that are primarily used by interventional cardiologists and heart surgeons. The firm's products are used for patients in need of hemodynamic support before, during, or after angioplasty and heart surgery procedures. Abiomed receives the majority of revenue from its Impella product portfolio, which includes percutaneous micro heart pumps with integration motors and sensors and percutaneous catheter-based axial flow pumps. Abiomed generates the majority of its revenue in the United States.